Night Owls May Be at Higher Risk of Cognitive Decline. Here's Why.
We all have our own chronotype – a tendency to sleep at certain times, with early birds and night owls at opposite ends of the scale. A new study suggests this chronotype has some relationship to cognitive decline in those who have completed higher education.
Led by a team from the University of Groningen in the Netherlands, the study dug into the data on 23,798 individuals aged 40 and over in a public health research database. Sleeping habits were charted against scores on the Ruff Figural Fluency Test (RFFT), measuring cognitive ability, across the course of a decade.
Night owls who stayed up late and had a university-level education had a higher risk of cognitive decline, the data showed. The findings add important new information to efforts to understand aging and dementia, including Alzheimer's disease.
"In the high-educational group each one-hour increase in chronotype corresponded to a 0.80-point decline in cognition per decade," write the researchers in their published paper.
"In this group, sleep quality and current smoking mediated 13.52 percent and 18.64 percent of the association, respectively."
In other words, the quality of the sleep these people were getting, and whether or not they were smokers, affected the cognitive decline risk somewhat – but only to a relatively small degree. Smoking and reduced sleep are known to be linked to dementia.
The study isn't thorough enough to show direct cause and effect between being a night owl and having a more rapid rate of cognitive decline – there are just too many variables to consider. However, it does show a relationship that's worth investigating, and certain key factors were accounted for in the statistics.
"Physical activity, past smoking, and alcohol consumption did not explain the association between chronotype and cognitive decline," write the researchers.
"In the low and middle-educational attainment subgroups, no significant total and direct effects were observed."
Results from previous studies into this particular association have been mixed, and were based on varying approaches, but there is plenty of past research on the relationship between sleep and our well-being – night shift workers are more at risk of numerous health issues, for example.
The researchers put forward some suggestions for why well-educated night owls may see more cognitive decline, including having working hours that are more fixed and regular – so still having to get up early in the morning, even if they've stayed up late, and thus not giving the brain time to fully rest.
That more well-educated people have a higher cognitive level to begin with – which means a drop-off could be more noticeable – is something else mentioned in the study. The researchers also note that their study sample involved a low number of early bird chronotypes, which may have influenced the results.
As populations get older across the world, there are estimated to be around 57 million cases of dementia globally – a number expected to more than double by 2050 – which makes efforts to find out the causes of cognitive decline an increasingly urgent one.
"With rising life expectancies and aging populations worldwide, preserving cognitive health is an urgent global priority," write the researchers.
The research has been published in the Journal of Prevention of Alzheimer's Disease.
Cannabis Compound Could Protect Us From Deadly Fungal Disease
Pooping Is a High-Stakes Event That Could Be Fatal For One Group
Misophonia Has Genetic Links to Depression And Anxiety, Study Finds
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 hours ago
- Yahoo
Alzheimer's blood test can accurately pick up early symptoms
A new blood test for Alzheimer's disease can accurately detect people with early symptoms, research suggests. Experts from the Mayo Clinic in the US have provided further evidence that blood tests can work to accurately diagnose dementia, by examining two proteins in blood plasma. These proteins – amyloid beta 42/40 and p-tau217 – are associated with amyloid plaque build-up, which is a hallmark of Alzheimer's disease. Researchers found the blood test was highly accurate, with 95% sensitivity, which means it was 95% accurate in picking up people with memory problems, with very few cases missed. It was also 82% for specificity, which means it was also highly accurate in ruling out people without dementia. The study was carried out on more than 500 people in an outpatient memory clinic, meaning it is real-world data. The blood test has already been approved by the Food and Drug Administration regulator in the US. Dr Gregg Day, who led the study in the Alzheimer's and Dementia journal, said the test was as good as more invasive tests currently in use. 'Our study found that blood testing affirmed the diagnosis of Alzheimer's disease with 95% sensitivity and 82% specificity,' he said. 'When performed in the outpatient clinical setting, this is similar to the accuracy of cerebrospinal fluid biomarkers of the disease and is much more convenient and cost-effective.' Overall, researchers found that p-tau217 levels were higher in patients with Alzheimer's disease versus those without the disease. Dr Day said the next steps in the research were to evaluate blood-based testing in more diverse patient populations and people with early Alzheimer's who show no cognitive symptoms. Dr Richard Oakley, associate director for research and innovation at the Alzheimer's Society in the UK, said the results 'suggest this test is very accurate' and could be used alongside other tests and observations from a trained health professional. "This study shows how blood tests are making diagnosis of Alzheimer's disease quicker, easier and more accessible than ever before in a real-world setting," he added. "While focused on Alzheimer's disease, the test was evaluated in people with other types of dementias too, showing that it may help with differentiate causes of cognitive decline – though more research in diverse groups of individuals and in community-based setting is still needed."
Yahoo
5 hours ago
- Yahoo
The Cause of Alzheimer's Might Be Coming From Within Your Mouth
In recent years, an increasing number of scientific investigations have backed an alarming hypothesis: Alzheimer's disease may not be merely a condition of an aging brain, but the product of infection. While the exact mechanisms of this infection are something researchers are still trying to isolate, numerous studies suggest the deadly spread of Alzheimer's goes way beyond what we used to think. One such study, published in 2019, suggested what could be one of the most definitive leads yet for a bacterial culprit behind Alzheimer's, and it comes from a somewhat unexpected quarter: gum disease. Watch the video below for a summary of their study: In a paper led by senior author Jan Potempa, a microbiologist from the University of Louisville, researchers reported the discovery of Porphyromonas gingivalis – the pathogen behind chronic periodontitis (aka gum disease) – in the brains of deceased Alzheimer's patients. It wasn't the first time the two factors have been linked, but the researchers went further. In separate experiments with mice, oral infection with the pathogen led to brain colonization by the bacteria, together with increased production of amyloid beta (Aβ), the sticky proteins commonly associated with Alzheimer's. The research team, coordinated by pharma startup Cortexyme, which was co-founded by first author Stephen Dominy, wasn't claiming to have discovered definitive evidence of Alzheimer's causation. But it was clear they thought we had a strong line of investigation here. P. gingivalis' gingipains (red) among neurons in the brain of a patient with Alzheimer's. (Cortexyme) "Infectious agents have been implicated in the development and progression of Alzheimer's disease before, but the evidence of causation hasn't been convincing," Dominy said at the time. "Now, for the first time, we have solid evidence connecting the intracellular, Gram-negative pathogen, P. gingivalis, and Alzheimer's pathogenesis." In addition, the team identified toxic enzymes called gingipains secreted by the bacteria in the brains of Alzheimer's patients, which correlated with two separate markers of the disease: the tau protein, and a protein tag called ubiquitin. But even more compellingly, the team identified these toxic gingipains in the brains of deceased people who were never diagnosed with Alzheimer's. That's important, because while P. gingivalis and the disease have been linked before, it's never been known – to put it simply – whether gum disease causes Alzheimers, or whether dementia leads to poor oral care. The fact that low levels of gingipains were evident even in people who were never diagnosed with Alzheimer's could be a smoking gun – suggesting they might have developed the condition if they had lived longer. "Our identification of gingipain antigens in the brains of individuals with AD and also with AD pathology but no diagnosis of dementia argues that brain infection with P. gingivalis is not a result of poor dental care following the onset of dementia or a consequence of late-stage disease, but is an early event that can explain the pathology found in middle-aged individuals before cognitive decline," the authors explained in their paper. Further, a compound formulated by the company called COR388, showed in experiments with mice that it could reduce bacterial load of an established P. gingivalis brain infection, while also reducing amyloid-beta production and neuroinflammation. We'll have to wait and see what future research will uncover about this link, but the research community is cautiously optimistic. "Drugs targeting the bacteria's toxic proteins have so far only shown benefit in mice, yet with no new dementia treatments in over 15 years it's important that we test as many approaches as possible to tackle diseases like Alzheimer's," chief scientific officer David Reynolds from Alzheimer's Research commented in a statement. The findings were reported in Science Advances. An earlier version of this story was published in January 2019. Common Diabetes Drug Linked to 'Exceptional Longevity' in Women Increased Toxicity Risk Identified For Children With ADHD, Autism Coffee Could Be The Secret to Healthy Aging For Women, Scientists Discover
Medscape
7 hours ago
- Medscape
Small Ear-Wax Sample, Big Diagnostic Clues
A recent BBC report suggests that cerumen, commonly known as earwax, may harbor biomarkers to aid in the diagnosis and monitoring of conditions such as cancer, Alzheimer's disease, and metabolic disorders. Cerumen Profile The primary function of cerumen is to keep the external auditory canal clean and lubricated, preventing invasion by bacteria, fungi, and insects. Beyond this, cerumen may reflect systemic metabolism by concentrating a broader array of compounds than blood, urine, sweat, and tears. Its relative stability allows the accumulated cerumen to provide long-term snapshots of metabolic changes. Disease Associations Researchers have defined genetically determined wet and dry cerumen phenotypes. In the US, Caucasian, African American, and German women with wet cerumen faced roughly four times the risk of dying from breast cancer compared with Japanese and Taiwanese women with dry cerumen. The study found that Japanese women with breast cancer were more likely to carry the wet-cerumen allele than were healthy controls. However, large-scale studies in Germany, Australia, and Italy failed to confirm these associations. A recent analysis reported that patients with Ménière's disease had lower levels of three fatty acids in the cerumen compared with healthy controls — the first biomarker identified for that disorder. In a 2019 study led by Nelson Roberto Antoniosi Filho, PhD (Federal University of Goiás Goiânia in Brazil), researchers analyzed cerumen samples from 52 patients with lymphoma, carcinoma, or leukemia and 50 healthy volunteers, using a method that identifies volatile organic compounds (VOCs). The researchers identified 27 VOCs that served as diagnostic fingerprints for cancer, predicting the cancer status with 100% accuracy. The assay could not distinguish among cancer types, indicating that these VOCs represent a general response to malignant cells. Another investigation by the same group showed that cerumen analysis can detect metabolic disturbances in premalignant stages when cells exhibit dysplastic changes that may lead to cancer but remain nonmalignant, potentially enabling much earlier intervention. The team is also investigating whether metabolic alterations caused by neurodegenerative diseases, such as Parkinson's disease and Alzheimer's disease, can be detected in the cerumen. Diagnostic Tool Antoniosi Filho and colleagues proposed that cancer, as a mitochondrial metabolic disorder, releases VOCs that accumulate in cerumen, allowing differentiation between healthy and cancerous individuals via an assay they call the cerumenogram. The aim was to develop a cerumenogram as a diagnostic tool to accurately predict certain cancers from a small cerumen sample. Clinical Adoption Hospital Amaral Carvalho in Jaú, São Paulo — a national reference center for oncology and bone marrow transplantation — has recently implemented cerumenograms for cancer diagnosis and monitoring. Future Directions An April 2025 paper in Scientific Reports by Antoniosi Filho concluded that the cerumenogram could: 1. Identify oncologic risk by detecting premalignant cells before cancer onset, introducing a novel screening modality 2. Show that mitochondrial impairment in premalignant cells — such as hypermetabolic inflammation and dysplasia — produces the same VOC biomarkers as malignant cells, distinct from those in benign lesions, opening new paths for risk management and early intervention 3. Correlate cerumenogram findings with established imaging techniques such as 2-deoxy-2-[fluorine-18] fluoro-D-glucose PET/CT (18F-FDG PET/CT) and gallium-68 PSMA PET/CT, demonstrating alignment with clinical results while offering a noninvasive, lower-cost alternative 4. Monitor treatment response and cancer remission, supporting assessment of therapeutic efficacy and cellular return to normal 5. Confirm metabolic indicators of malignancy to guide clinical decisions alongside imaging and biopsy 6. Drive the development of targeted therapies aimed at metabolites overproduced in malignant conditions. In conclusion, the cerumenogram may serve as a valuable assay for evaluating precancerous indicators, cancer progression, and remission, with the potential to reduce mortality, alleviate patient suffering, and lower disease-related costs. Congratulations to Nelson Roberto Antoniosi Filho, PhD, and his team.
